On September 9, 2015, potential subject nine of 12 was enrolled in our ongoing study of MDMA-assisted therapy for social anxiety in 12 adults on the autism spectrum. One subject chose to leave the study, and is counted as a drop-out. Sponsored by MAPS, this is a collaborative study between MAPS and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, with blood plasma biomarker analysis being conducted by researchers at Stanford University. “No Serious Adverse Events have occurred, and the study has received 228 screening inquiries from across the United States and several other countries,” reports study Co-Investigator Alicia Danforth, Ph.D. “One of the key factors contributing to this study running smoothly since the launch was early and ongoing consultation with members of the autism community.”
